We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rosetta to Raise $2.2 Million in Registered Direct Offering
News

Rosetta to Raise $2.2 Million in Registered Direct Offering

Rosetta to Raise $2.2 Million in Registered Direct Offering
News

Rosetta to Raise $2.2 Million in Registered Direct Offering

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Rosetta to Raise $2.2 Million in Registered Direct Offering"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Rosetta Genomics, Ltd. has announced that it has entered into definitive agreements with investors to purchase an aggregate of 632,057 ordinary shares at a price of $3.50 per share in a registered direct offering.

The offering is expected to close on or about May 22, 2012, subject to the satisfaction of customary closing conditions.

Rosetta plans to use the net proceeds from the offering primarily to fund its operations and for other general corporate purposes, including, but not limited to, repayment or refinancing of existing indebtedness or other corporate borrowings, working capital, intellectual property protection and enforcement, capital expenditures, investments, acquisitions or collaborations, research and development and product development.

Aegis Capital Corp. acted as the exclusive placement agent for the offering.

A shelf registration statement relating to the securities offered and sold in the offering has been filed with the Securities and Exchange Commission (the "SEC") and has been declared effective.

A final prospectus supplement relating to the offering will be filed by Rosetta with the SEC.

Copies of the final prospectus supplement and accompanying prospectus may be obtained directly from Rosetta by contacting Rosetta Genomics Ltd., 10 Plaut Street, Science Park, Rehovot 76706, Israel or via telephone at 215-382-9000 ext. 309.

Advertisement